Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Reuters NewMedia - Saturday December 16, 2000
The protein, called alpha-1 antitrypsin (AAT), seems to prevent the AIDS virus from infecting cells, the team at the University of Colorado Health Sciences Center reports.
"In the laboratory, we confirmed the surprising observation that the AIDS virus did not grow in blood," Dr. Leland Shapiro, an assistant professor of medicine who led the study, said in a statement.
"This suggested that there was at least one substance in the blood that blocked the virus. We believe we have identified one of the substances as AAT."
In a study to be published in the Federation of the American Societies of Experimental Biology (FASEB) Journal, Shapiro and colleagues said AAT works in several ways against the virus.
Looking at blood donated to the American Red Cross, Shapiro and colleagues saw the HIV virus did not proliferate when added to blood from healthy volunteers, but it did when added to blood from patients who had genetic defects that caused them to have low levels of AAT.
They also found, working in the laboratory, that AAT blocked the ability of the virus to infect previously healthy, uninfected cells.
And in cells infected with HIV, adding AAT to the lab dish virtually stopped the virus's ability to spread out of the cell.
Shapiro said it may be that the virus reproduces in areas naturally low in AAT. They think it might be possible to give extra AAT to HIV-infected patients.
"These findings are preliminary but promising," Shapiro said. "If clinical results are as promising as what we have seen in the laboratory, methods of increasing AAT or use of an AAT 'mimic' might be an effective form of AIDS therapy."
He said he would propose running tests in humans.
AAT is used to treat patients with cystic fibrosis and other genetic defects. It is being grown in the milk of genetically engineered animals by PPL Therapeutics, the Scotland-based company involved in cloning the first mammal, Dolly the sheep, in 1997.
001216
RE001228
Copyright © 2000 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .